FY2025 · period end Dec '25 · from the 10-K filed Feb 20, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Gross Profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B |
| Operating Income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| EPS (Diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $52.77B | $47.90B | $38.83B | $36.91B | $36.02B |
| Cash & Equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B |
| Capital Expenditures | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B |
| Free Cash Flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% |
| Operating Margin | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Net Margin | 0.1% | 0.3% | 0.1% | 0.2% | 0.2% |
| Return on Equity | 13.0% | 30.9% | 15.1% | 19.0% | 20.5% |
| Return on Assets | 7.8% | 17.3% | 7.8% | 9.3% | 9.6% |
| Debt / Equity | 0.30× | 0.32× | 0.41× | 0.52× | 0.52× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001628280-26-028357 | Mar 31, 2026 | Apr 29, 2026 | Apr 29, 2026 20:05 UTC | EDGAR |
| 8-K | 0001104659-26-049434 | Apr 24, 2026 | Apr 27, 2026 | Apr 27, 2026 20:06 UTC | EDGAR |
| 8-K | 0001104659-26-044892 | Apr 10, 2026 | Apr 17, 2026 | Apr 17, 2026 20:04 UTC | EDGAR |
| 8-K | 0001628280-26-025365 | Apr 16, 2026 | Apr 16, 2026 | Apr 16, 2026 11:36 UTC | EDGAR |
| 8-K | 0001104659-26-033079 | Mar 23, 2026 | Mar 23, 2026 | Mar 23, 2026 12:54 UTC | EDGAR |
| 8-K | 0001104659-26-025240 | Mar 9, 2026 | Mar 9, 2026 | Mar 9, 2026 20:21 UTC | EDGAR |
| 8-K | 0001104659-26-020509 | Feb 23, 2026 | Feb 26, 2026 | Feb 26, 2026 21:16 UTC | EDGAR |
| 10-K | 0001628280-26-010185 | Dec 31, 2025 | Feb 20, 2026 | Feb 20, 2026 21:05 UTC | EDGAR |
Direct links to SEC EDGAR. ABT has additional filings available on the SEC site.
6 numbers ABBOTT LABORATORIES later changed — same XBRL tag, both filings linked.
Income (Loss) from Continuing Operations before Income Taxes, Domestic·FY 2012
Major restatementwas-$620M
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q3 2012
Major restatementwas$1.9B
Revised down in a 10-Q.
Operating Income (Loss)·Q3 2012
Major restatementwas$2B
Revised down in a 10-Q.
Operating Income (Loss)·FY 2012
Major restatementwas$8.1B
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Foreign·FY 2012
Major restatementwas$6.9B
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2011
Major restatementwas$5.2B
Revised down in a 10-K.
ABT is not the only one.
See every restatement we've found across the market — or get an alert the next time ABT revises a number.
Restatements are detected by comparing every vintage of a fact across all of ABBOTT LABORATORIES's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ABT's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling ABBOTT LABORATORIES — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ABT yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ABT and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs